Idexx Laboratories, Inc [IDXX] stock prices are down -0.11% to $722.12 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The IDXX shares have gain 13.83% over the last week, with a monthly amount glided 15.03%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Idexx Laboratories, Inc [NASDAQ: IDXX] stock has seen the most recent analyst activity on October 31, 2025, when Stifel upgraded its rating to a Buy but kept the price target unchanged to $700 for it. Previously, UBS started tracking the stock with Neutral rating on October 01, 2025, and set its price target to $720. On August 05, 2025, BTIG Research reiterated its Buy rating and revised its price target to $785 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $625 on July 01, 2025. Leerink Partners initiated its recommendation with a Outperform and recommended $500 as its price target on December 02, 2024. BTIG Research started tracking with a Buy rating for this stock on July 25, 2024, and assigned it a price target of $580. In a note dated January 30, 2024, Piper Sandler downgraded a Neutral rating on this stock but restated the target price of $525.
The stock price of Idexx Laboratories, Inc [IDXX] has been fluctuating between $356.14 and $735.00 over the past year. Currently, Wall Street analysts expect the stock to reach $795.83 within the next 12 months. Idexx Laboratories, Inc [NASDAQ: IDXX] shares were valued at $722.12 at the most recent close of the market. An investor can expect a potential return of 10.21% based on the average IDXX price forecast.
Analyzing the IDXX fundamentals
The Idexx Laboratories, Inc [NASDAQ:IDXX] reported sales of 4.17B for trailing twelve months, representing a surge of 13.29%. Gross Profit Margin for this corporation currently stands at 0.62% with Operating Profit Margin at 0.31%, Pretax Profit Margin comes in at 0.31%, and Net Profit Margin reading is 0.25%. To continue investigating profitability, this company’s Return on Assets is posted at 0.3, Equity is 0.68 and Total Capital is 0.61. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 710.31 points at the first support level, and at 698.49 for the second support level. However, for the 1st resistance point, the stock is sitting at 730.22, and for the 2nd resistance point, it is at 738.31.
Ratios To Look Out For
It’s worth pointing out that Idexx Laboratories, Inc [NASDAQ:IDXX]’s Current Ratio is 1.18. On the other hand, the Quick Ratio is 0.87, and the Cash Ratio is 0.17. Considering the valuation of this stock, the price to sales ratio is 13.86, the price to book ratio is 37.00 and price to earnings (TTM) ratio is 57.26.
Transactions by insiders
Recent insider trading involved SZOSTAK M ANNE, Director, that happened on Aug 22 ’25 when 2187.0 shares were sold. Director, MARGARET ANNE SZOSTAK completed a deal on Aug 22 ’25 to buy 2187.0 shares. Meanwhile, Executive Vice President Erickson Michael G sold 406.0 shares on Aug 12 ’25.
